BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China – Reuters
|
BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … Intellia Therapeutics Announces Patent for CRISPR/Cas Genome …GuruFocus.com Intellia Therapeutics Inc – Receive News & Ratings DailyBBNS |
|
J&J Immunotherapy Darzalex Ok’d for Expanded Combination Use
Zacks.com Johnson & Johnson (JNJ – Free Report) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation’s (CELG – Free Report) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone. |
|
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
Nasdaq BASEL, Switzerland, June 19, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that China’s State Intellectual … Intellia Therapeutics (NTLA) Receives Patent for CRISPR/Cas …StreetInsider.com Intellia Therapeutics Announces Patent for CRISPR/Cas Genome …GuruFocus.com Intellia Therapeutics Inc (NTLA) Expected to Announce Earnings of -$0.41 Per ShareSports Perspectives High Point Observer –Equities.com all 17 news articles » |
|
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
GlobeNewswire (press release) BASEL, Switzerland, June 19, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that China’s State Intellectual … |
|
Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
GlobeNewswire (press release) CAMBRIDGE, Mass., June 19, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, today announced that China’s … Insider Selling: CRISPR THERAPTC (CRSP) CEO Sells 50000 Shares of StockStock Observer CRISPR Therapeutics AG (:CRSP) Shares Tick 1.44% For the WeekConcord Register Crispr Therapeutics AG (CRSP) Expected to Announce Earnings of -$0.49 Per ShareTranscript Daily Davidson Register all 8 news articles » |